Ultra-deep sequencing detects ovarian cancer cells in peritoneal fluid and reveals somatic TP53 mutations in noncancerous tissues

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 21, 2016, Pages 6005-6010

  Krimmel, Jeffrey D ^a   Schmitt, Michael W ^a   Harrell, Maria I ^b   Agnew, Kathy J ^b   Kennedy, Scott R ^a   Emond, Mary J ^a   Loeb, Lawrence A ^a   Swisher, Elizabeth M ^b   Risques, Rosa Ana ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Clonal hematopoiesis; Ovarian cancer; Premalignant mutations; Tp53 mutations; Ultra deep sequencing

Indexed keywords

DOUBLE STRANDED DNA; PROTEIN P53; TP53 PROTEIN, HUMAN;

AGE; ARTICLE; BLOOD SAMPLING; CANCER PATIENT; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DNA STRAND; EARLY CANCER DIAGNOSIS; FEMALE; GENE SEQUENCE; HUMAN; OVARY CARCINOMA; PERITONEAL FLUID; PERITONEUM METASTASIS; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SOMATIC MUTATION; TUMOR SUPPRESSOR GENE; ADULT; AGED; ASCITES FLUID; GENETICS; HIGH THROUGHPUT SEQUENCING; METABOLISM; MIDDLE AGED; MUTATION; OVARY TUMOR; PATHOLOGY;

ADULT; AGED; ASCITIC FLUID; FEMALE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MIDDLE AGED; MUTATION; OVARIAN NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84969850944     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1601311113     Document Type: Article

References (38)

1. Fox EJ, Reid-Bayliss KS, Emond MJ, Loeb LA (2014) Accuracy of next generation sequencing platforms. Next Gener Seq Appl 1:106.
2. Bettegowda C, et al. (2014) Detection of circulating tumor DNA in early- and latestage human malignancies. Sci Transl Med 6(224):224ra24.
3. Wang Y, et al. (2015) Detection of somatic mutations and HPV in the saliva and plasma of patients with head and neck squamous cell carcinomas. SciTranslMed7(293):293ra104.
4. Wang Y, et al. (2015) Detection of tumor-derived DNA in cerebrospinal fluid of patients with primary tumors of the brain and spinal cord. Proc Natl Acad Sci USA 112(31):9704-9709.
5. Kinde I, et al. (2013) Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers. Sci Transl Med 5(167):167ra4.
6. Kinde I, Wu J, Papadopoulos N, Kinzler KW, Vogelstein B (2011) Detection and quantification of rare mutations with massively parallel sequencing. Proc Natl Acad Sci USA 108(23):9530-9535.
7. Schmitt MW, et al. (2012) Detection of ultra-rare mutations by next-generation sequencing. Proc Natl Acad Sci USA 109(36):14508-14513.
8. Schmitt MW, et al. (2015) Sequencing small genomic targets with high efficiency and extreme accuracy. Nat Methods 12(5):423-425.
9. Badgwell D, Bast RC, Jr (2007) Early detection of ovarian cancer. Dis Markers 23(5-6): 397-410.
10. Kindelberger DW, et al. (2007) Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. Am J Surg Pathol 31(2):161-169.
11. Kurman RJ, Shih IeM (2010) The origin and pathogenesis of epithelial ovarian cancer: A proposed unifying theory. Am J Surg Pathol 34(3):433-443.
12. Przybycin CG, Kurman RJ, Ronnett BM, Shih IeM, Vang R (2010) Are all pelvic (nonuterine) serous carcinomas of tubal origin? Am J Surg Pathol 34(10):1407-1416.
13. Prat J; FIGO Committee on Gynecologic Oncology (2014) Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet 124(1):1-5.
14. Maritschnegg E, et al. (2015) Lavage of the uterine cavity for molecular detection of Müllerian duct carcinomas: A proof-of-concept study. J Clin Oncol 33(36):4293-4300.
15. Cancer Genome Atlas Research Network (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474(7353):609-615.
16. Vang R, et al. (2016) Molecular alterations of TP53 are a defining feature of ovarian high-grade serous carcinoma: A rereview of cases lacking TP53 mutations in the Cancer Genome Atlas ovarian study. Int J Gynecol Pathol 35(1):48-55.
17. Kuhn E, et al. (2012) TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma: Evidence supporting the clonal relationship of the two lesions. J Pathol 226(3):421-426.
18. Norquist BM, et al. (2010) The molecular pathogenesis of hereditary ovarian carcinoma: Alterations in the tubal epithelium of women with BRCA1 and BRCA2 mutations. Cancer 116(22):5261-5271.
19. Swisher EM, et al. (2005) Tumor-specific p53 sequences in blood and peritoneal fluid of women with epithelial ovarian cancer. Am J Obstet Gynecol 193(3 Pt 1):662-667.
20. Walsh T, et al. (2011) Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci USA 108(44):18032-18037.
21. Hjortsberg L, et al. (2008) The p53 Mutation Handbook, Version 2.0. Available at p53. free.fr. Accessed November 2015.
22. Petitjean A, et al. (2007) Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: Lessons from recent developments in the IARC TP53 database. Hum Mutat 28(6):622-629.
23. Petitjean A, Achatz MI, Borresen-Dale AL, Hainaut P, Olivier M (2007) TP53 mutations in human cancers: Functional selection and impact on cancer prognosis and outcomes. Oncogene 26(15):2157-2165.
24. Soussi T, et al. (2010) MUT-TP53 2.0: A novel versatile matrix for statistical analysis of TP53 mutations in human cancer. Hum Mutat 31(9):1020-1025.
25. Alexandrov LB, et al. (2015) Clock-like mutational processes in human somatic cells. Nat Genet 47(12):1402-1407.
26. Alexandrov LB, et al.; Australian Pancreatic Cancer Genome Initiative; ICGC Breast Cancer Consortium; ICGC MMML-Seq Consortium; ICGC PedBrain (2013) Signatures of mutational processes in human cancer. Nature 500(7463):415-421.
27. Martincorena I, Campbell PJ (2015) Somatic mutation in cancer and normal cells. Science 349(6255):1483-1489.
28. Genovese G, et al. (2014) Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med 371(26):2477-2487.
29. Jacobs KB, et al. (2012) Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet 44(6):651-658.
30. Jaiswal S, et al. (2014) Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med 371(26):2488-2498.
31. Laurie CC, et al. (2012) Detectable clonal mosaicism from birth to old age and its relationship to cancer. Nat Genet 44(6):642-650.
32. Wong TN, et al. (2015) Role of TP53 mutations in the origin and evolution of therapyrelated acute myeloid leukaemia. Nature 518(7540):552-555.
33. Xie M, et al. (2014) Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med 20(12):1472-1478.
34. Kipps E, Tan DS, Kaye SB (2013) Meeting the challenge of ascites in ovarian cancer: New avenues for therapy and research. Nat Rev Cancer 13(4):273-282.
35. Score J, et al. (2015) Detection of leukemia-associated mutations in peripheral blood DNA of hematologically normal elderly individuals. Leukemia 29(7):1600-1602.
36. Martincorena I, et al. (2015) Tumor evolution: High burden and pervasive positive selection of somatic mutations in normal human skin. Science 348(6237):880-886.
37. Loeb LA (2011) Human cancers express mutator phenotypes: Origin, consequences and targeting. Nat Rev Cancer 11(6):450-457.
38. Kennedy SR, et al. (2014) Detecting ultralow-frequency mutations by Duplex Sequencing. Nat Protoc 9(11):2586-2606.